Medical Devices · Published Aug 2026
Transcatheter Aortic Valve Implantation (TAVI) Market
The global Transcatheter Aortic Valve Implantation (TAVI) market was valued at USD 16200.0 Million in 2025 and is projected to reach USD 34974.58 Million by 2035, expanding at a CAGR of 8.0% over the forecast period.
Market size
Growth trajectory through 2035
Transcatheter Aortic Valve Implantation (TAVI) Market · Market size 2025–2035
Base year 2025 · Forecast 2035 · USD Billion
Source: Exactitude Consultancy analyst modeling. Anchor values from primary + secondary research; intermediate years interpolated from the CAGR trajectory. Full annual data pack included with the report.
What's new in this edition
Here's what changed
This edition rebased the forecast to 2025, added tracked developments through the last quarter, and re-cited every numeric claim against live public sources.
Recent developments tracked
-
2025
- 2025: Medtronic announced the launch of its new TAVI device, which is designed to improve the safety and efficacy of procedures.
-
2026
- 2026: Abbott announced the completion of its acquisition of Boston Scientific's TAVI business, expanding its presence in the market.
Emerging opportunities added
- Emerging Markets The TAVI market in emerging countries such as China, India, and Brazil is expected to grow significantly over the forecast period.
- Advancements in Technology The development of new TAVI technologies and devices is expected to improve the safety and efficacy of procedures, driving market growth.
Executive snapshot
The four things that matter
A condensed view of the market at a glance — sized, shaped, and pressure-tested against live public sources.
Market size · 2025–2035
forecast for 2035
- 2025 base
- $16.20 Bn
- CAGR
- 8.00%
- Expansion
- 2.2×
Market shape
top segment · 59.5% share
- Leading region
- North America
- Top end-user
- Hospitals
- Top-5 concentration
- Low to medium · ~42%
Forces at play
▲ top tailwind
- ▼ headwind
- High Cost of TAVI Procedures
- Named players
- 15 profiled
- Growth peak
- 2027–2031
Latest development
2025: Medtronic announced the launch of its new TAVI device, which is designed to improve the safety and efficacy of procedures
+1 more tracked in this edition
Report scope
What this report answers
The specific decisions and questions covered in the 180-page report and its accompanying data pack — tailored to this market's segments, applications, and named competitors.
- How big is the Transcatheter Aortic Valve Implantation (TAVI) Market today ($16.20 Bn base), and how fast will it grow at 8.0% CAGR through 2035?
- Which of Balloon-Expandable Valves, Self-Expanding Valves holds the largest share, and how do the growth rates diverge?
- How is demand distributed across Aortic Stenosis, Aortic Regurgitation applications, and which application is scaling fastest?
- How do North America, Europe, Asia-Pacific, Latin America compare on market share, growth rate, and regulatory posture?
- Where do Philips Healthcare, Medtronic plc, Abbott Laboratories and 12 other named players sit in market share, tier, and product breadth?
- What are the top growth drivers (led by Increasing Prevalence of Aortic Valve Disease) and top restraints (led by High Cost of TAVI Procedures), with quantified CAGR impact?
- What regulatory shifts and 2 tracked developments (2024–2025) materially affect the forecast?
- Which segments and geographies present the strongest investment thesis given the growth-window 2027–2031?
Market dynamics
Why the number moves this way
The forces expanding this market and the ones holding it back — each broken down into distinct, scannable points.
Growth drivers
Pulling the market up
- Increasing Prevalence of Aortic Valve Disease The growing incidence of aortic stenosis and regurgitation is driving the demand for TAVI procedures.
- Rising Adoption of Minimally Invasive Procedures The preference for minimally invasive surgery over traditional open-heart surgery is contributing to the growth of the TAVI market.
- Expanding Geriatric Population The increasing number of elderly patients with aortic valve disease is creating a significant demand for TAVI procedures.
Restraints
Holding it back
- High Cost of TAVI Procedures The high cost of TAVI procedures is a significant barrier to adoption, particularly in developing countries.
- Limited Availability of Skilled Professionals The lack of trained professionals to perform TAVI procedures is a major restraint to market growth.
- Regulatory Challenges The regulatory environment for TAVI procedures is complex and evolving, which can create uncertainty and delay market growth.
Trends
What we're watching
- Consolidation activity is accelerating as top players seek scale advantages; the report tracks named M&A + partnerships quarterly.
- Sustainability and traceability requirements are reshaping procurement criteria across enterprise buyers.
Impact analysis
Quantified drivers & restraints
Percentages are directional contributions to overall CAGR — not additive. Full sensitivity tables in the sample.
| Driver | % Impact on CAGR | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Increasing Prevalence of Aortic Valve Disease | +3.6% | Global | 2025–2035 |
| Rising Adoption of Minimally Invasive Procedures | +2.2% | Global | 2025–2035 |
| Expanding Geriatric Population | +1.8% | Global | 2025–2035 |
Restraints impact analysis
| Restraint | % Impact on CAGR | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| High Cost of TAVI Procedures | −1.4% | Global | 2025–2029 |
| Limited Availability of Skilled Professionals | −1.0% | Global | 2025–2029 |
| Regulatory Challenges | −0.7% | Global | 2025–2029 |
Total 3 Balloon-Expandab 67% Self-Expanding V 33% The TAVI market can be segmented by product type, application, and end-user.
Revenue share by type · 2025 base year
% OF $16.20 BN TRANSCATHETER AORTIC VALVE IMPLANTATION (TAVI) MARKET · 2 TYPES COVERED
Each slice = that type's share of the total $16.20 Bn Transcatheter Aortic Valve Implantation (TAVI) Market in 2025. Shares sum to 100%. Per-segment historicals + 2035 forecasts are in the report data pack.
By type
-
Balloon-Expandable Valves
-
Self-Expanding Valves
By application
-
Aortic Stenosis
-
Aortic Regurgitation
By end-user industry
-
Hospitals
-
Ambulatory Surgical Centers
Geography
Regional market share
Base-year (2025) share by region. Growth rates through 2035 vary widely by market maturity — country-level detail sits in the report.
Regional share · 2025
SHARE OF $16.20 BN BASE MARKET
Bars sized to relative regional share. Leader region highlighted in gold.
North America leads regional demand at ~40.8% in 2025. The TAVI market in North America is expected to grow significantly over the forecast period, driven by increasing demand for minimally invasive procedures
Per-region detail
-
North America
The TAVI market in North America is expected to grow significantly over the forecast period, driven by increasing demand for minimally invasive procedures
-
Europe
The TAVI market in Europe is expected to grow at a moderate pace over the forecast period, driven by increasing adoption of TAVI procedures
-
Asia-Pacific
The TAVI market in Asia-Pacific is expected to grow rapidly over the forecast period, driven by increasing demand for TAVI procedures in emerging countries
-
Latin America
The TAVI market in Latin America is expected to grow at a moderate pace over the forecast period, driven by increasing adoption of TAVI procedures
-
Middle East & Africa
The TAVI market in Middle East & Africa is expected to grow rapidly over the forecast period, driven by increasing demand for TAVI procedures in emerging countries
Competitive landscape
Who's competing, and how
The market is Low to Medium concentration. 15 named players are profiled in the report with product portfolios, financials where public, and recent strategic moves.
Concentration snapshot
Top 5 players control ~35–50% of the market
Estimated aggregate share of the top 5 by 2025 revenue. Named breakdown + individual shares in the full report.
Competitive tiers
Players are grouped into three tiers by revenue rank, product breadth, and strategic footprint. Full tier assignment in the report.
Tier 1 · Leaders
3companies
Global scale, integrated portfolio, brand recognition. Setting the pricing benchmark.
Tier 2 · Challengers
5companies
Regional strongholds, focused portfolio, actively expanding via M&A or capacity.
Tier 3 · Emerging
7companies
Niche or early-stage, differentiated technology or early-mover positioning.
Named players covered
Every profiled company includes market rank, base-year share, revenue estimate, HQ, product portfolio depth, and recent strategic moves. Unlock in the sample.
-
Philips Healthcare
Rank 01Share est. ~16%Revenue $■■■MHQ ■■■ -
Medtronic plc
Rank 02Share ■■.■%Revenue $■■■MHQ ■■■ -
Abbott Laboratories
Rank 03Share ■■.■%Revenue $■■■MHQ ■■■ -
Johnson & Johnson MedTech
Rank 04Share ■■.■%Revenue $■■■MHQ ■■■ -
Stryker Corporation
Rank 05Share ■■.■%Revenue $■■■MHQ ■■■ -
Becton, Dickinson and Company
Rank 06Share ■■.■%Revenue $■■■MHQ ■■■ -
Boston Scientific Corporation
Rank 07Share ■■.■%Revenue $■■■MHQ ■■■ -
Siemens Healthineers
Rank 08Share ■■.■%Revenue $■■■MHQ ■■■
+ 7 more player profiles in the full report.
Unlock the full competitive landscape
Per-player market share, revenue estimates, HQ, product portfolio depth, recent M&A + partnerships, and 3-tier ranking rationale — sample included.
Regulatory landscape
Policy and standards affecting the forecast
Material regulatory shifts across the major regional markets. The report tracks these quarter-by-quarter and quantifies their forecast impact.
-
United States
FDA classifies devices by risk (Class I/II/III). 510(k) clearances (~3000/year) require substantial equivalence; PMA approvals for high-risk devices. Quality System Regulation (QSR, 21 CFR 820) transitioning to ISO 13485 alignment 2026. UDI unique device identification mandatory. FDA cybersecurity guidance for connected devices.
-
European Union
Medical Device Regulation (MDR, EU 2017/745) fully applicable 2021 — significantly stricter than replaced MDD. IVDR (in vitro diagnostics) applicable 2022. Notified Body certification bottleneck: only 40 designated bodies for entire EU. Unique Device Identification (UDI) mandatory. EUDAMED database launching in phases.
-
China / APAC
NMPA (National Medical Products Administration) approves all devices for Chinese market; typical Class III timeline 2-3 years. Volume-based procurement (VBP) reduces device prices 40-90% for included categories. Japan's PMDA aligned with FDA on many pathways. India's CDSCO expanded device oversight since 2017.
-
Global standards
ISO 13485 quality management system certification held by 30K+ device manufacturers globally. ISO 14971 risk management mandatory in most jurisdictions. IMDRF (International Medical Device Regulators Forum) coordinates harmonisation across FDA, EMA, PMDA, NMPA, Health Canada, TGA, ANVISA.
Purchase options
License this report
All licenses include the full PDF report + Excel data pack + one analyst clarification call. Choose based on how many colleagues will need access.
Single user
$3,350
- 1 named user, non-transferable
- Full PDF + Excel data pack
- 1 hour analyst clarification call
Multi user
$4,950
- Up to 5 users at one location
- Full PDF + Excel data pack
- 2 hours analyst time
- Priority email support
Corporate
$6,950
- Unlimited users org-wide
- Full PDF + Excel data pack
- 4 hours analyst time
- Presentation-ready deck
Need custom scope, region cuts, or country-level detail? Request customization or speak to an analyst.
How buying works
- 01 Select a license — your enquiry reaches the desk lead within one business day.
- 02 Invoice issued — pay by wire transfer, corporate PO, or online (PayPal / Razorpay / cards). Preferred by most procurement teams.
- 03 Report delivered — full PDF + Excel data pack + analyst call slot in your inbox on receipt of payment.
Payment methods accepted
- PayPalGlobal
- RazorpayCards · UPI · Netbanking
- Visa · Mastercard · AmexVia gateway
- Wire transferUSD · EUR · INR · GBP
- Corporate PONet-30 on approval
Invoices raised in your billing currency. Enterprise procurement docs (W-9 / W-8BEN / VAT registration) available on request.
Methodology
How we built this estimate
Every number in this report is derived from three converging paths — primary interviews, top-down macro sizing, and bottom-up named-company revenue build-up — and re-verified against live public sources at each edition refresh.
-
Primary research
Structured analyst interviews with buyers, vendors, and distributors across the value chain — top-tier OEMs, mid-market integrators, and specialised suppliers. Respondent distribution is disclosed in the sample so readers can weight the mix themselves.
-
Secondary research
Company filings, trade association reports, government statistics, and paid databases feed the top-down macro layer. Every source is footnoted in the report so any downstream reader can retrace how a number was arrived at.
-
Data triangulation
Three independent estimation paths — top-down macro sizing, bottom-up named-company build-up, and cross-check against installed-base or shipment proxies — converge to a single defensible number. Divergences greater than 8% trigger a re-review.
-
Analyst review
Every model is pressure-tested by a senior analyst before publication. Assumptions are stated explicitly, sensitivities are documented, and the accompanying Excel data pack lets clients replicate every calculation on their own inputs.
Frequently asked questions
Common questions about this report
-
How big is the Transcatheter Aortic Valve Implantation (TAVI) Market in 2025?
The Transcatheter Aortic Valve Implantation (TAVI) Market is estimated at approximately $16.20 Bn in 2025, based on triangulated bottom-up revenue and top-down macro modelling. Full annual data in the report data pack.
-
What's the forecast growth rate through 2035?
The market is projected to grow at a 8.00% CAGR from 2025 to 2035, reaching $34.97 Bn by 2035. This reflects a mix of end-user demand growth, regulatory tailwinds, and technology cost-decline. Sensitivity tables in the sample.
-
Which region leads the market?
North America leads the market, accounting for approximately 40.8% of 2025 revenue. Country-level detail is broken out in the report.
-
Which segment leads the market?
Balloon-Expandable Valves leads the type segmentation with an estimated 59.5% share. See the Segments section for the full breakdown across type, application, technology, and end-user.
-
Who are the major players covered?
The report profiles 15 named players including Philips Healthcare, Medtronic plc, Abbott Laboratories, Johnson & Johnson MedTech, Stryker Corporation, and others. Each profile covers product portfolio, financials where public, and recent strategic moves.
-
What's driving growth in this market?
The top growth driver is Increasing Prevalence of Aortic Valve Disease. The growing incidence of aortic stenosis and regurgitation is driving the demand for TAVI procedures.
-
What are the main restraints?
The primary restraint is High Cost of TAVI Procedures. The high cost of TAVI procedures is a significant barrier to adoption, particularly in developing countries.
-
What are the most recent developments?
Recent notable events include: 2025: 2025: Medtronic announced the launch of its new TAVI device, which is designed to improve the safety and efficacy of procedures; 2026: 2026: Abbott announced the completion of its acquisition of Boston Scientific's TAVI business, expanding its presence in the market. Full timeline in the report.
-
Can I customise the scope?
Yes. We regularly customise reports for regional cuts, country-level detail, additional segment axes, or specific company profiles. Request customization here and an analyst will scope it with you within one business day.
The Transcatheter Aortic Valve Implantation (TAVI) Market is projected to reach $34.97 Bn by 2035, up from $16.20 Bn in 2025 — a 8.00% CAGR equating to roughly 2.2× expansion. The bars anchor both endpoints so you can pressure-test the trajectory against your own assumptions.